Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Similar articles for PubMed (Select 18004635)

1.

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Selmaj K, Uitdehaag BM, Dahms S, Bauer L, Pohl C, Sandbrink R; BENEFIT investigators.

J Neurol. 2008 Apr;255(4):480-7. Epub 2007 Nov 15.

PMID:
18004635
2.

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R.

Neurology. 2006 Oct 10;67(7):1242-9. Epub 2006 Aug 16.

PMID:
16914693
3.

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, Pohl C, Sandbrink R.

Arch Neurol. 2007 Sep;64(9):1292-8.

PMID:
17846268
4.

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.

Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM.

BMC Neurol. 2009 May 20;9:19. doi: 10.1186/1471-2377-9-19.

5.

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group.

Lancet. 2007 Aug 4;370(9585):389-97.

PMID:
17679016
7.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F.

Arch Neurol. 2009 Nov;66(11):1345-52. doi: 10.1001/archneurol.2009.243.

PMID:
19901165
8.

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.

Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.

PMID:
19279320
9.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group.

Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10.

PMID:
19748319
11.

Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.

O'Connor P, Kinkel RP, Kremenchutzky M.

Mult Scler. 2009 Jun;15(6):728-34. doi: 10.1177/1352458509103173.

PMID:
19482863
12.

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

CHAMPS Study Group.

Am J Ophthalmol. 2001 Oct;132(4):463-71.

PMID:
11589865
13.

Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.

Pakdaman H, Sahraian MA, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A.

Acta Neurol Scand. 2007 Jun;115(6):429-31.

PMID:
17511854
14.

A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.

Rovira A, Swanton J, Tintoré M, Huerga E, Barkhof F, Filippi M, Frederiksen JL, Langkilde A, Miszkiel K, Polman C, Rovaris M, Sastre-Garriga J, Miller D, Montalban X.

Arch Neurol. 2009 May;66(5):587-92. doi: 10.1001/archneurol.2009.49.

PMID:
19433658
15.

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.

Neurology. 1999 Jan 15;52(2):351-9.

PMID:
9932956
16.

Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.

Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson AJ, Miller DH.

Mult Scler. 2010 Feb;16(2):156-65. doi: 10.1177/1352458509353650. Epub 2010 Jan 19.

PMID:
20086028
17.

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b.

Lazzaro C, Bianchi C, Peracino L, Zacchetti P, Uccelli A.

Neurol Sci. 2009 Feb;30(1):21-31. doi: 10.1007/s10072-009-0015-0. Epub 2009 Jan 24.

PMID:
19169625
18.
19.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group.

Lancet. 2001 May 19;357(9268):1576-82.

PMID:
11377645
20.

Interferon-beta-1b: in newly emerging multiple sclerosis.

McKeage K.

CNS Drugs. 2008;22(9):787-92. Review.

PMID:
18698876
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk